SCHEMBL4634501

SCHEMBL4634501

CCOC(=O)c1sc2ccccc2c1OCC(=O)c1ccc(OC)c(Cl)c1Cl

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.60
LMNA P02545 4/20 0.60
GAA P10253 3/20 0.60
NPSR1 Q6W5P4 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
KMT2A Q03164 4/20 0.52
ALDH1A1 P00352 4/20 0.52
NOD2 Q9HC29 1/20 0.50
MEN1 O00255 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
TP53 P04637 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
KDM4E B2RXH2 2/20 0.44
F10 P00742 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 2/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4633973 0.88 MAPT (0.74) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4634997 0.88 PTPN2 (0.47) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4635019 0.86 MAPT (0.48) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4632979 0.86 L3MBTL1 (0.60) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4605523 0.85 MAPT (0.43) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4634481 0.80 ALDH1A1 (0.60) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4635064 0.80 ALDH1A1 (0.72) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL1381986 0.78 MAPT (0.69) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4634448 0.78 KMT2A (0.73) MAPTLMNAGAANPSR1L3MBTL1
SCHEMBL4633865 0.78 LMNA (0.59) MAPTLMNAGAANPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685121-B1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2008-06-11 EP claimed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US claimed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US claimed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US disclosed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US disclosed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US disclosed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives GPR119, INSR, GLP1R MAPT 2481/4885LMNA 3220/4885GAA 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.